Standard BioTools Inc.
LAB Healthcare Medical Devices
In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow LAB
Standard BioTools Inc. (LAB) P/E ratio
As of 16 October 2026, Standard BioTools Inc. (LAB) trades at a P/E ratio of 2.9×. Over the past ten years it has ranged from 0.0× (March 2026) to 6.4× (June 2026); the current reading is higher than 95% of that period. That is below the Medical Devices industry median of 23.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 3.7× | (18.97%) |
| Mar 2026 | 4.6× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLPT ClearPoint Neuro, Inc. compare | n/m |
| QSI Quantum-Si Incorporated compare | n/m |
| TLSI TriSalus Life Sciences, Inc. compare | n/m |
| TMCI Treace Medical Concepts, Inc. compare | n/m |
| PROF Profound Medical compare | n/m |
| CATX Perspective Therapeutics, Inc. compare | n/m |
| LAB Standard BioTools Inc. | 2.9× |
| ELMD Electromed, Inc. compare | 20.0× |
| INFU InfuSystems Holdings, Inc. compare | 31.7× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)